» Articles » PMID: 39900965

Inhibition of GPR68 Induces Ferroptosis and Radiosensitivity in Diverse Cancer Cell Types

Overview
Journal Sci Rep
Date 2025 Feb 3
PMID 39900965
Authors
Affiliations
Soon will be listed here.
Abstract

Radioresistance is thought to be a major consequence of tumor milieu acidification resulting from the Warburg effect. Previously, using ogremorphin (OGM), a small molecule inhibitor of GPR68, an extracellular proton sensing receptor, we demonstrated that GPR68 is a key pro-survival pathway in glioblastoma cells. Here, we demonstrate that GPR68 inhibition also induces ferroptosis in lung cell carcinoma (A549) and pancreatic ductal adenocarcinoma (Panc02) cells. Moreover, OGM synergized with ionizing radiation to induce lipid peroxidation, a hallmark of ferroptosis, as well as reduce colony size in 2D and 3D cell culture. GPR68 inhibition is not acutely detrimental but increases intracellular free ferrous iron, which is known to trigger reactive oxygen species (ROS) generation. In summary, GPR68 inhibition induces lipid peroxidation in cancer cells and sensitizes them to ionizing radiation in part through the mobilization of intracellular free ferrous iron. Our results suggest that GPR68 is a key mediator of cancer cell radioresistance activated by acidic tumor microenvironment.

References
1.
Adjemian S, Oltean T, Martens S, Wiernicki B, Goossens V, Vanden Berghe T . Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death. Cell Death Dis. 2020; 11(11):1003. PMC: 7684309. DOI: 10.1038/s41419-020-03209-y. View

2.
Li W, Sun X . Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments. Recent Pat Anticancer Drug Discov. 2018; 13(4):455-468. DOI: 10.2174/1574892813666180831102519. View

3.
Nguyen H, Shabani S, Awad A, Kaushal M, Doan N . Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. Int J Mol Sci. 2018; 19(6). PMC: 6032212. DOI: 10.3390/ijms19061765. View

4.
Xiao Y, Yu D . Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2020; 221:107753. PMC: 8084948. DOI: 10.1016/j.pharmthera.2020.107753. View

5.
Glickstein H, El R, Shvartsman M, Cabantchik Z . Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005; 106(9):3242-50. DOI: 10.1182/blood-2005-02-0460. View